Triazole derivatives with improved in vitro antifungal activity over azole drugs

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 383-390

  Yu, Shichong ^a   Chai, Xiaoyun ^a   Wang, Yanwei ^a   Cao, Yongbing ^a   Zhang, Jun ^a   Wu, Qiuye ^a   Zhang, Dazhi ^a   Jiang, Yuanying ^a   Yan, Tianhua ^b   Sun, Qingyan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Azole agents; CYP51; Molecular docking; Synthesis

Indexed keywords

1 (2 [2,4 DIFLUOROPHENYL] 2 HYDROXY 3 [1H 1,2,4 TRIAZOL 1 YL]PROPYL)PIPERIDIN 4 OL; 1 (2 [2,4 DIFLUOROPHENYL] 2 HYDROXY 3 [1H 1,2,4 TRIAZOL 1 YL]PROPYL)PIPERIDIN 4 YL 2 PHENYLACETATE; FERRIC ION; FLUCONAZOLE; FLUORINE; HALOGEN; IRON; ITRACONAZOLE; PIPERIDINE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ARTHRODERMA GYPSEUM; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG BINDING; DRUG DESIGN; DRUG INTERACTION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FONSECAEA; FONSECAEA COMPACTA; GROWTH INHIBITION; HYDROGEN BOND; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; THIN LAYER CHROMATOGRAPHY; TRICHOPHYTON RUBRUM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIFUNGAL AGENTS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84898660012     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S58680     Document Type: Article

References (27)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001; 33(10): 1692-1696.
2. Ablordeppey SY, Fan P, Ablordeppey JH, Mardenborough L. Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development. Curr Med Chem. 1999; 6(12): 1151-1195.
3. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses. 1998; 41(7-8): 309-319.
4. Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol. 1998; 1(5): 547-557.
5. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 1996; 40(2): 279-291.
6. Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect. 2003; 53(4): 243-258.
7. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998; 11(2): 382-402.
8. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy. 2003; 23(11): 1441-1462.
9. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999; 12(4): 501-517.
10. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999; 12(1): 40-79.
11. Sheng CQ, Zhang WN, Ji HT, et al. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking. J Med Chem. 2006; 49(8): 2512-2525.
12. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3, 685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother. 2001; 45(10): 2862-2864.
13. Lepesheva GI, Hargrove TY, Ott RD, Nes WD, Waterman MR. Biodiversity of CYP51 in trypanosomes. Biochem Soc Trans. 2006; 34(Pt 6): 1161-1164.
14. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011; 86(8): 805-817.
15. Di Santo R, Tafi A, Costi R, et al. Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1 H-pyrrol-3-yl) methyl]-1 H-imidazole: synthesis, anti-candida activity, and QSAR studies. J Med Chem. 2005; 48(16): 5140-5153.
16. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003; 11(6): 272-279.
17. Shyadehi AZ, Lamb DC, Kelly SL, et al. The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha-demethylase of Candida albicans (other names are: lanosterol 14 alpha-demethylase, P-45014DM, and CYP51). J Biol Chem. 1996; 271(21): 12445-12450.
18. Chai X, Zhang J, Hu H, et al. Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14 alpha-demethylase. Eur J Med Chem. 2009; 44(5): 1913-1920.
19. Chai X, Zhang J, Yu S, et al. Design, synthesis, and biological evaluation of novel 1-(1H-1, 2, 4-triazole-1-yl)-2-(2, 4-difluorophenyl)-3-substituted benzylamino-2-propanols. Bioorg Med Chem Lett. 2009; 19(6): 1811-1814.
20. Chai X, Zhang J, Cao Y, et al. New azoles with antifungal activity: Design, synthesis, and molecular docking. Bioorg Med Chem Lett. 2011; 21(2): 686-689.
21. Chai X, Zhang J, Cao Y, et al. Design, synthesis and molecular docking studies of novel triazole as antifungal agent. Eur J Med Chem. 2011; 46(7): 3167-3176.
22. Jiang Y, Cao Y, Zhang J, et al. Design, synthesis and antifungal evaluation of 1-(2-(2, 4-difluorophenyl)-2-hydroxy-3-(1H-1, 2, 4-triazol-1-yl)propyl)-1H-1, 2, 4-triazol-5(4H)-one. Eur J Med Chem. 2011; 46(7): 3135-3141.
23. Xu J, Cao Y, Zhang J, et al. Design, synthesis and antifungal activities of novel 1, 2, 4-triazole derivatives. Eur J Med Chem. 2011; 46(7): 3142-3148.
24. Aoyama Y, Yoshida Y, Nishino T, et al. Isolation and characterization of an altered cytochrome P-450 from a yeast mutant defective in lanosterol 14 alpha-demethylation. J Biol Chem. 1987; 262(29): 14260-14264.
25. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved standard. Document M38-A3, Wayne, PA; 2002.
26. Ji HT, Zhang WN, Zhang M, et al. Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14 alpha-demethylase of fungi. J Med Chem. 2003; 46(4): 474-485.
27. Ji H, Zhang W, Zhou Y, et al. A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem. 2000: 43(13): 2493-2505.